AF solution
Oncology
Immuno Oncology
Anti-Virus
Disease Modeling
Cosmetics
Toxicity
Spatial Biology
Technology Service
Cancer Organoid
Research Service
Others
Organism | |
Product Type | Organoid |
Tissue | Breast mammary gland, Mammary duct |
Disease | Breast cancer |
Applications
Drug Test (Organoid Only)
Establishing a process for isolating cytotoxic T cells that can directly attack cancer cells, creating an MHC-TCR interaction environment, and utilizing MHC I/II blockers to achieve an immune microenvironment in vivo.
Using Immune Cell Co-culture
Establishing a process for isolating cytotoxic T cells that can directly attack cancer cells, creating an MHC-TCR interaction environment, and utilizing MHC I/II blockers to achieve an immune microenvironment in vivo.
Using Cancer Associate Fibroblast
Establishing a process for isolating cytotoxic T cells that can directly attack cancer cells, creating an MHC-TCR interaction environment, and utilizing MHC I/II blockers to achieve an immune microenvironment in vivo.
Experience cutting-edge innovation with our Human Breast Cancer Organoids, leveraging advanced 3D cell culture technology to accurately replicate the microenvironment of human breast cancer tissues.
These organoids exemplify the heterogeneity of the disease, providing a dynamic platform for studying cancer progression and testing new treatments.
Dive into a new era of research that brings us closer to understanding and combating breast cancer.
Breast cancer organoid
Unlock groundbreaking insights into breast cancer with our Human Breast Cancer (hBC) Organoids.
These advanced models accurately replicate the expression patterns of key markers ER, PR, and HER2, mirroring patient tumors with high fidelity.
This molecular mimicry not only deepens our understanding of breast cancer pathology but also paves the way for the development of personalized treatments.
Discover a promising path to therapeutic innovation with our hBC organoids, where every study brings us closer to targeted cancer solutions.
H&E | ER | PR | ERBB2/HER2 | |
|---|---|---|---|---|
Cancer tissue |  |  |  |  |
Cancer organoid |  |  |  |  |
Our cutting-edge platform has demonstrated the ability to precisely assess drug responses, offering insights into the effectiveness of medications against specific cancer profiles.
This breakthrough empowers personalized medicine, enabling the development of tailored treatments that are as unique as each patient’s needs.
Join us in transforming cancer therapy and enhancing patient outcomes with precision.
hBC-23-005
Carboplatin
hBC-23-005
Cisplatin
hBC-23-005
Paclitaxel
@ 2024 . All rights reserved
@ 2024 . All rights reserved
